US Stock MarketDetailed Quotes

PODD Insulet

Watchlist

200.450
-1.390-0.69%

Close Jun 14 16:00 ET

201.250
+0.800+0.40%

Post 19:14 ET

14.04BMarket Cap60.20P/E (TTM)

Insulet Stock Forum

103493112

Jun 13 07:32

Nvidia completed stock split: Can the tech giant sustain its glory?

moom lives

Mar 27 22:23

Here are the WORST 10 S&P 500 stock performers in Q1 (YTD):
Tesla $Tesla(TSLA.US)$ : -28.50% 🔻
Boeing $Boeing(BA.US)$ : -28.07% 🔻
MarketAxess $MarketAxess(MKTX.US)$ : -26.75% 🔻
Warner Bros $Warner Bros Discovery(WBD.US)$ : -26.36% 🔻
Charter Communications $Charter Communications(CHTR.US)$ : -25.93% 🔻
Lululemon $Lululemon Athletica(LULU.US)$ : -24.48% 🔻
VF Corp $VF Corp(VFC.US)$ : -24.15% 🔻
Humana $Humana(HUM.US)$ : -23.90% 🔻
Insulet $Insulet(PODD.US)$ : -23.72% 🔻
Paramount $Paramount Global-B(PARA.US)$ : -23.12%...

108M

Mar 18 08:53

$Insulet(PODD.US)$Here's Why You Should Buy Insulet (PODD) Stock Right Now

Lucy88888

Feb 22 15:26

$Insulet(PODD.US)$ Why it drops?

Moomoo AI

Feb 19 04:28

Despite low ROCE, Insulet's consistent reinvestment at increasing rates and growing capital employed are positive signs. The stock's 112% return over five years shows investor optimism.

Insulet (NASDAQ:PODD) Is Looking To Continue Growing Its Returns On Capital

Moomoo AI

Feb 5 06:20

Positive EPS growth and share price decrease may signal an opportunity for investors. Long term shareholders gained 19% annually over five years. The recent sell-off could be a chance if fundamentals indicate long term growth.

Those Who Invested in Insulet (NASDAQ:PODD) Five Years Ago Are up 134%

Moomoo AI

Dec 26, 2023 13:34

Baird analysts anticipate Insulet's earnings to grow faster than their annual sales of approx. 20%. DexCom's margins predicted to expand with sales growth over 20% annually before GLP-1s impact. Boston Scientific considered a top-level medtech enterprise by Baird's Rescott.

3 Medical-Device Stocks Could Click in 2024 -- Barrons.com

Moomoo AI

Dec 25, 2023 09:12

Insulet may be overvalued, with the company's promising outlook already priced in, leaving no upside from mispricing. Investors advised to await a price drop.